Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Mycophenolate Mofetil in C3 glomerulopathy and pathogenic drivers of the disease

  • Caravaca-Fontán, Fernando
  • Díaz-Encarnación, Montserrat M.
  • Lucientes, Laura
  • Cavero, Teresa
  • Cabello-Chaves, Virginia
  • Ariceta, Gema
  • Quintana, Luis F.
  • Marco, Helena
  • Barros, Xoana
  • Ramos, Natalia
  • Rodríguez-Mendiola, Nuria
  • Cruz, Sonia
  • Fernández-Juárez, Gema
  • Rodríguez, Adela
  • Pérez de José, Ana
  • Rabasco, Cristina
  • Rodado, Raquel
  • Fernández, Loreto
  • Pérez Gómez, Vanessa
  • Ávila, Ana
  • Bravo, Luis
  • Lumbreras, Javier
  • Allende, Natalia
  • Sánchez de la Nieta, María Dolores
  • Rodríguez, Eva
  • Olea, Teresa
  • Melgosa, Marta
  • Huerta, Ana
  • Miquel, Rosa
  • Mon, Carmen
  • Fraga, Gloria
  • de Lorenzo, Alberto
  • Cano-Megías, Marta
  • González, Fayna
  • Shabaka, Amir
  • López-Rubio, María Esperanza
  • Fenollosa, María Ángeles
  • Martín-Penagos, L.
  • Da Silva, Iara
  • Alonso Titos, Juana
  • Rodríguez de Córdoba, Santiago
  • Goicoechea de Jorge, Elena
  • Praga, Manuel
12 p.-4 fig.-4 tab., BACKGROUND AND OBJECTIVES: C3 glomerulopathy is a complement-mediated disease arising from abnormalities in complement genes and/or antibodies against complement components. Previous studies showed that treatment with corticosteroids plus mycophenolate mofetil (MMF) was associated with improved outcomes, although the genetic profile of these patients was not systematically analyzed. This study aims to analyze the main determinants of disease progression and response to this therapeutic regimen., DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a retrospective, multicenter, observational cohort study in 35 nephrology departments belonging to the Spanish Group for the Study of Glomerular Diseases. Patients diagnosed with C3 glomerulopathy (n=81) or dense deposit disease (n=16) between January 1995 and March 2018 were enrolled. Multivariable and propensity score matching analyses were used to evaluate the association of clinical and genetic factors with response to treatment with corticosteroids and MMF as measured by proportion of patients with disease remission and kidney survival (status free of kidney failure)., RESULTS: The study group comprised 97 patients (84% C3 glomerulopathy, 16% dense deposit disease). Forty-two patients were treated with corticosteroids plus MMF, and this treatment was associated with a higher rate of remission and lower probability of kidney failure (79% and 14%, respectively) compared with patients treated with other immunosuppressives (24% and 59%, respectively), or ecluzimab (33% and 67%, respectively), or conservative management (18% and 65%, respectively). The therapeutic superiority of corticosteroids plus MMF was observed both in patients with complement abnormalities and with autoantibodies. However, patients with pathogenic variants in complement genes only achieved partial remission, whereas complete remissions were common among patients with autoantibody-mediated forms. The main determinant of no remission was baseline proteinuria. Relapses occurred after treatment discontinuation in 33% of the patients who had achieved remission with corticosteroids plus MMF, and a longer treatment length of MMF was associated with a lower risk of relapse., CONCLUSIONS: The beneficial response to corticosteroids plus MMF treatment in C3 glomerulopathy appears independent of the pathogenic drivers analyzed in this study., Work in this study was supported by the Instituto de Salud CarlosIII/ Fondo Europeo de Desarrollo Regional (ISCIII/FEDER) grant PI16/01685 and Red de Investigación Renal (RedInRen) (RD12/0021/0029) (to M. Praga), and the Autonomous Region of Madrid (S2017/BMD-3673) (to S. Rodríguez de Córdoba and M. Praga).E. Goicoechea de Jorge is supported by the Spanish “Ministerio de Ciencia, Innovación y Universidades” (RYC-2013-13395 and RTI2018-095955-B-100). S. Rodríguez de Córdoba is supported by Ministerio de Economía y Competitividad/FEDER grant SAF2015-66287R and Autonomous Region of Madrid grant S2017/BMD3673., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Molecular bases for the association of FHR-1 with atypical hemolytic uremic syndrome and other diseases, Short title: Molecular understanding of FHR-1 function

  • Martín Merinero, Héctor
  • Subías, Marta
  • Pereda, Amaia
  • Gomez-Rubio, Elena
  • Juana-López, Lucía
  • Fernández Rivera, Constantino
  • Goicoechea de Jorge, Elena
  • Martín-Santamaría, Sonsoles
  • Cañada, F. Javier
  • Rodríguez de Córdoba, Santiago
33 p.-7 fig., Factor H-related proteins (FHRs) are a group of partly characterized complement proteins that are thought to promote complement activation by competing binding of factor H (FH) to surface-bound C3b. Among them, FHR-1 is remarkable because is associated with atypical hemolytic uremic syndrome (aHUS) and other important diseases. Using a combination of biochemical, immunological, nuclear magnetic resonance and computational approaches, we have characterized a series of FHR-1 mutants (including two associated with aHUS) and have unraveled the molecular bases of the so-called de-regulation activity of FHR-1. In contrast with FH,FHR-1 lacks the capacity to bind sialic acids, which prevents C3b-binding competition between FH and FHR-1 in host cell surfaces. aHUS-associated FHR-1 mutants are pathogenic because they have acquired the capacity to bind sialic acids, which increases FHR-1 avidity for surface-bound C3-activated fragments and results in C3b-binding competition with FH. FHR-1 binds to native C3, in addition to C3b, iC3b and C3dg.This unexpected finding suggests that the mechanism by which surface-bound FHR-1 promotes complement activation is the attraction of native C3 to the cell surface. Whilst C3b-binding competition with FH is limited to aHUS-associated mutants, all surfacebound FHR-1 promote complement activation, which is delimited by the FHR-1/FH activity ratio. Our data indicate that the FHR-1 de-regulation activity is important to sustain complement activation and C3 deposition at complement activating surfaces.They also support that abnormally elevated FHR-1/FH activity ratios would perpetuate a pathological complement dysregulation at complement activating surfaces, which may explain the association of FHR-1 quantitative variations with diseases., SRdeC, FJC and SMS are supported by the Spanish “Ministerio de Economía y Competitividad-FEDER” grants (SAF2015-66287-R, RTI2018-094751-B-C22, and CTQ2017-88353-R, respectively) and the Autonomous Region of Madrid (S2017/BMD-3673). EGdeJ is supported by the Spanish “Ministerio de Ciencia, Innovación y Universidades-FEDER (RYC-2013-13395 and RTI2018-095955-B-100)., Peer reviewed